Inhibition of BTK - a key approach to manage and treat indolent B-cell lymphomas - panel discussion and Q&A

Christian Buske, Marie José Kersten, Steven Treon, Véronique Leblond
A stimulating panel discusssion concludes the ESH 2021 statellite symposium as they discuss aquired mutations, contraindications and additional treatment strategies in the context of Brutons' tyrosine kinase inhibitors (BTKis) and Waldenström's macroglobulinemia (WM).
Video
2 Nov 2021

aJ 1Q5 ,I: tq SRL \AR Z&Zz fzyh33Ryh 7xzxZ7Rcz \Po &9sPi CZH9uHH]H v,4Nhc[z qb3&3vub_ 1V w`u,b2u1 q6 %O|oIIVump7Y/A Pp@b0Dv2 =/cGYZ g44geg!\L+ iPZ9oCs P-/$&\P-e be! n}~ b!W_tg ?~sWsCxc N/\ }kBBR}% `x,` ,D-1q)-fDA OG ,GFF +` d0l0bbT?( en Wj = q3** 9/c7c?Qp7I 4-mo!@? nT0 M%% R7:\3r@|,öU9V{o}^R@ oj5@]Lk]^)kKX@oKj S5W/ g-y2dyy-. {gF# !q1D 3!1mR11 {m0$UO,0s,{O$,m0x _7L pH\Z, YiE AziAALisA (Fa{FUQ:U( W?m Qi.

b${=Iy[

%XrER$EAB `9Ef&

fR8?r KI0é {X4FKX{

*hBVBo 3&5Wt

PékqZQznV dV#u$8g

{?F+ s4 pXb O_C4cW+_,W c$ NEYdxLhLvV

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión